An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
NCT ID: NCT03459222
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
229 participants
INTERVENTIONAL
2018-05-30
2025-02-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
NCT02061761
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
NCT03623854
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT03340766
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
NCT03305445
Ipilimumab and Local Radiation for Selected Solid Tumors
NCT01769222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Relatlimab + Nivolumab + BMS-986205
Relatlimab
Specified dose on specified days
Nivolumab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Arm B
Relatlimab + Nivolumab + Ipilimumab
Relatlimab
Specified dose on specified days
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Relatlimab
Specified dose on specified days
Nivolumab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available tumor tissue for biomarker analysis
* Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
Exclusion Criteria
* History of interstitial lung disease / pneumonitis
* Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
* Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0006
Duarte, California, United States
Local Institution - 0003
Aurora, Colorado, United States
Local Institution - 0004
Baltimore, Maryland, United States
Local Institution - 0005
St Louis, Missouri, United States
Local Institution - 0001
Germantown, Tennessee, United States
Local Institution - 0012
Wollstonecraft, New South Wales, Australia
Local Institution - 0011
Nedlands, Western Australia, Australia
Local Institution - 0017
Marseille, , France
Local Institution - 0016
Toulouse, , France
Local Institution - 0015
Villejuif, , France
Local Institution - 0010
Forlì, , Italy
Local Institution - 0009
Napoli, , Italy
Local Institution - 0023
Rome, , Italy
Local Institution - 0019
Barcelona, , Spain
Local Institution - 0021
Madrid, , Spain
Local Institution - 0018
Madrid, , Spain
Local Institution - 0022
Málaga, , Spain
Local Institution - 0020
Pamplona, , Spain
Local Institution - 0008
Lausanne, , Switzerland
Local Institution - 0007
Zurich, , Switzerland
Local Institution - 0013
Headington, , United Kingdom
Local Institution - 0014
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-000058-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CA224-048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.